Thermo-reversible injectable gel based on enzymatically-chopped low molecular weight methylcellulose for exenatide and FGF 21 delivery to treat types 1 and 2 diabetes

Journal of Controlled Release

Volumn 194, Issue , 2014, Pages 316-322

  Kim, Jang Kyoung ^a   Yoo, Changhun ^a   Cha, Yong Hoon ^a   Kim, Yong Hee ^a  

^a Hanyang University   (South Korea)

Author keywords

Diabetes; Enzymatically chopped low molecular weight; methylcellulose; Protein delivery; Thermo reversible gel

Indexed keywords

INJECTABLE GEL; LOW MOLECULAR WEIGHT; METHYLCELLULOSE; PROTEIN DELIVERY; THERMOREVERSIBLE GELS;

MEDICAL PROBLEMS;

EXENDIN 4; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; METHYLCELLULOSE; ANTIDIABETIC AGENT; FIBROBLAST GROWTH FACTOR; GEL; GLUCOSE BLOOD LEVEL; PEPTIDE; PHARMACEUTICAL VEHICLES AND ADDITIVES; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYMATIC DEGRADATION; GEL PERMEATION CHROMATOGRAPHY; GLUCOSE BLOOD LEVEL; HYDROGEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOLECULAR WEIGHT; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GEL; METABOLISM; THERMODYNAMICS; TISSUE DISTRIBUTION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FIBROBLAST GROWTH FACTORS; GELS; HYPOGLYCEMIC AGENTS; MALE; METHYLCELLULOSE; MICE; MICE, INBRED BALB C; MOLECULAR WEIGHT; PEPTIDES; PHARMACEUTIC AIDS; THERMODYNAMICS; TISSUE DISTRIBUTION; VENOMS;

EID: 84907706342     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.09.014     Document Type: Article

References (30)

1. F. Whitehouse, D.F. Kruger, M. Fineman, L. Shen, J.A. Ruggles, D.G. Maggs, C. Weyer, and O.G. Kolterman A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes Diabetes Care 25 2002 724 730
2. F.M. Brunkhorst, C. Engel, F. Bloos, A. Meier-Hellmann, M. Ragaller, N. Weiler, O. Moerer, M. Gruendling, M. Oppert, S. Grond, D. Olthoff, U. Jaschinski, S. John, R. Rossaint, T. Welte, M. Schaefer, P. Kern, E. Kuhnt, M. Kiehntopf, C. Hartog, C. Natanson, M. Loeffler, and K. Reinhart Intensive insulin therapy and pentastarch resuscitation in severe sepsis N. Engl. J. Med. 358 2008 125 139
3. S. Heller Weight gain during insulin therapy in patients with type 2 diabetes mellitus Diabetes Res. Clin. Pract. 65 2004 S23 S27 (Supplement)
4. J. Dupré, M.T. Behme, and T.J. McDonald Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes J. Clin. Endocrinol. Metab. 89 2004 3469 3473
5. A. Kharitonenkov, T.L. Shiyanova, A. Koester, A.M. Ford, R. Micanovic, E.J. Galbreath, G.E. Sandusky, L.J. Hammond, J.S. Moyers, R.A. Owens, J. Gromada, J.T. Brozinick, E.D. Hawkins, V.J. Wroblewski, D.-S. Li, F. Mehrbod, S.R. Jaskunas, and A.B. Shanafelt FGF-21 as a novel metabolic regulator J. Clin. Invest. 115 2005 1627 1635
6. A. Beenken, and M. Mohammadi The FGF family: biology, pathophysiology and therapy Nat. Rev. Drug Discov. 8 2009 235 253
7. C.B. Packhaeuser, J. Schnieders, C.G. Oster, and T. Kissel In situ forming parenteral drug delivery systems: an overview Eur. J. Pharm. Biopharm. 58 2004 445 455
8. B.K. Nanjawade, F.V. Manvi, and A.S. Manjappa In situ-forming hydrogels for sustained ophthalmic drug delivery J. Control. Release 122 2007 119 134
9. K.Y. Lee, and S.H. Yuk Polymeric protein delivery systems Prog. Polym. Sci. 32 2007 669 697
10. W.H. Tan, and S. Takeuchi Monodisperse alginate hydrogel microbeads for cell encapsulation Adv. Mater. 19 2007 2696 2701
11. S. Chakraborty, I.C. Liao, A. Adler, and K.W. Leong Electrohydrodynamics: a facile technique to fabricate drug delivery systems Adv. Drug Deliv. Rev. 61 2009 1043 1054
12. K.L.C.J. Coester, H. Von Briesen, and J. Kreuter Gelatin nanoparticles by two step desolvation a new preparation method, surface modifications and cell uptake J. Microencapsul. 17 2000 187 193
13. Y.W. Won, S.M. Yoon, K.S. Lim, and Y.H. Kim Self-assembled nanoparticles with dual effects of passive tumor targeting and cancer-selective anticancer effects Adv. Funct. Mater. 22 2012 1199 1208
14. Y.W. Won, S.M. Yoon, C.H. Sonn, K.M. Lee, and Y.H. Kim Nano self-assembly of recombinant human gelatin conjugated with alpha-tocopheryl succinate for Hsp90 inhibitor, 17-AAG, delivery ACS Nano 5 2011 3839 3848
15. J.K. Kim, Y.W. Won, K.S. Lim, and Y.H. Kim Low-molecular-weight methylcellulose-based thermo-reversible gel/pluronic micelle combination system for local and sustained docetaxel delivery Pharm. Res. 29 2012 525 534
16. Y.-W. Won, J.-K. Kim, M.-J. Cha, K.-C. Hwang, D. Choi, and Y.-H. Kim Prolongation and enhancement of the anti-apoptotic effects of PTD-Hsp27 fusion proteins using an injectable thermo-reversible gel in a rat myocardial infarction model J. Control. Release 144 2010 181 189
17. P. Zheng, L. Li, X. Hu, and X. Zhao Sol-gel transition of methylcellulose in phosphate buffer saline solutions J. Polym. Sci. B Polym. Phys. 42 2004 1849 1860
18. B. Jeong, S.W. Kim, and Y.H. Bae Thermosensitive sol-gel reversible hydrogels Adv. Drug Deliv. Rev. 54 2002 37 51
19. E. Ruel-Gari?y, and J.-C. Leroux In situ-forming hydrogels - review of temperature-sensitive systems Eur. J. Pharm. Biopharm. 58 2004 409 426
20. K.M. Jin, and Y.H. Kim Injectable, thermo-reversible and complex coacervate combination gels for protein drug delivery J. Control. Release 127 2008 249 256
21. R. Adden, C. Melander, G. Brinkmalm, L. Gorton, and P. Mischnick New approaches to the analysis of enzymatically hydrolyzed methyl cellulose. Part 1. Investigation of the influence of structural parameters on the extent of degradation Biomacromolecules 7 2006 1399 1409
22. C. Melander, R. Adden, G. Brinkmalm, L. Gorton, and P. Mischnick New approaches to the analysis of enzymatically hydrolyzed methyl cellulose. Part 2. Comparison of various enzyme preparations Biomacromolecules 7 2006 1410 1421
23. D.M. Lavin, L. Zhang, S. Furtado, R.A. Hopkins, and E. Mathiowitz Effects of protein molecular weight on the intrinsic material properties and release kinetics of wet spun polymeric microfiber delivery systems Acta Biomater. 9 2013 4569 4578
24. E. Watson, D.M. Jonker, L.V. Jacobsen, and S.H. Ingwersen Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide J. Clin. Pharmacol. 50 2010 886 894
25. O.G. Kolterman, D.D. Kim, L. Shen, J.A. Ruggles, L.L. Nielsen, M.S. Fineman, and A.D. Baron Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus Am. J. Health Syst. Pharm. 62 2005 173 181
26. M. Behme, J. Dupre, and T. McDonald Glucagon-like peptide 1 improved glycemic control in type 1 diabetes BMC Endocr. Disord. 3 2003 3
27. V.S. Raman, K.J. Mason, L.M. Rodriguez, K. Hassan, X. Yu, L. Bomgaars, and R.A. Heptulla The role of adjunctive exenatide therapy in pediatric type 1 diabetes Diabetes Care 33 2010 1294 1296
28. H. Kurosu, and M. Kuro The Klotho gene family as a regulator of endocrine fibroblast growth factors Mol. Cell. Endocrinol. 299 2009 72 78
29. T. Coskun, H.A. Bina, M.A. Schneider, J.D. Dunbar, C.C. Hu, Y. Chen, D.E. Moller, and A. Kharitonenkov Fibroblast growth factor 21 corrects obesity in mice Endocrinology 149 2008 6018 6027
30. P. Arner, A. Pettersson, P.J. Mitchell, J.D. Dunbar, A. Kharitonenkov, and M. Ryden FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity FEBS Lett. 582 2008 1725 1730